-
Sale!
Foundational and emerging principles driving pharmaceutical manufacturing excellence in the digital age. -
Sale!
Comprehensive guide to establishing 16 critical QMS elements aligned with FDA and ICH standards. -
Sale!
14 critical success factors for medical device contract manufacturers including QMS and cybersecurity. -
Sale!
Comprehensive cGMP framework covering quality standards digital transformation and cybersecurity in 2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart B – Quality System Requirements (§820.20 Management responsibility, §820.22 Quality audit, §820.25 Personnel). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart C – Design Controls (§820.30). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart D – Document Controls (§820.40). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart E – Purchasing Controls (§820.50). Form 483 observations and Warning Letters 2017–2025. -
FDA enforcement citation analysis for 21 CFR Part 820 Subpart F – Identification and Traceability (§820.60 Identification, §820.65 Traceability). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart G – Production and Process Controls (§820.70, §820.72 Inspection/measuring/test equipment, §820.75 Process validation). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart H – Acceptance Activities (§820.80 Receiving/in-process/finished device acceptance, §820.86 Acceptance status). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart I – Nonconforming Product (§820.90). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart J – Corrective and Preventive Action (§820.100 CAPA). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart K – Labeling and Packaging Control (§820.120 Device labeling, §820.130 Device packaging). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart L – Handling, Storage, Distribution, and Installation (§820.140, §820.150, §820.160, §820.170). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart M – Records (§820.180 General requirements, §820.181 Device master record, §820.184 Device history record, §820.186 Quality system record, §820.198 Complaint files). Form 483 observations and Warning Letters 2017–2025. -
Sale!
FDA enforcement citation analysis for 21 CFR Part 820 Subpart N – Servicing (§820.200) and Subpart O – Statistical Techniques (§820.250). Form 483 observations and Warning Letters 2017–2025. -
Sale!
Comprehensive framework for ALCOA++ compliance and regulatory expectations in data integrity programs. -
Sale!
Essential framework for pharmaceutical manufacturing excellence through comprehensive microbiological contamination control strategies and best practices. -
Sale!
Strategic guide to change control as enabler of innovation aligned with FDA QMSR and ISO 13485:2016 requirements. -
Sale!
Strategic insights on design controls, cybersecurity, and QMSR transition for medical device manufacturers navigating AI-enabled technologies. -
Sale!
Strategic approach to medical device quality system improvements addressing QMSR harmonization and cybersecurity requirements. -
Sale!
Framework for establishing and implementing KPIs to drive quality management system continuous improvement and organizational excellence. -
Sale!
FDA regulatory trends and risk management strategies for clinical development of drugs and devices. -
Sale!
Analysis of pharmaceutical cGMP compliance risk and regulatory enforcement trends 2023-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart D (Equipment) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart E (Control of Components and Drug Product Containers and Closures) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive regulation-by-regulation analysis of FDA CFR Part 211 Subpart F (Production and Process Controls) with direct links to Form 483 observations and Warning Letters from 2017-2025. -
Sale!
Comprehensive packaging and labeling enforcement data 2017-2025 -
Comprehensive holding and distribution enforcement data 2017-2025 -
Sale!
Comprehensive laboratory controls enforcement data 2017-2025 -
Sale!
Comprehensive records and reports enforcement data 2017-2025 -
Sale!
Quality by Design (QbD) is a paradigm shift that redefines quality assurance in pharmaceutical manufacturing by building quality into product and process design rather than relying solely on end-product testing.
ComplyFDA delivers authoritative compliance intelligence for pharmaceuticals, medical devices, biologics, and combination products, giving your team the clarity needed to strengthen inspection readiness, evaluate compliance risks, and support continuous quality improvement.
services.
get in touch.
© 2012 - 2026 • Avada is a Website Builder for WordPress and eCommerce • All Rights Reserved • Developed by ThemeFusion
